BIIB BIOGEN INC.
Price Chart
Executive Summary
Piper Sandler double upgraded Biogen (BIIB) from Neutral to Overweight, raising its price target to $214 from $177, a 21% increase. The firm, which has a 71% accuracy rate on 7 BIIB calls, cited improving fundamentals. Consensus is already bullish with 61% Buy ratings (27 of 44 analysts). The mean PT is $220.63, implying 10.3% upside from the current $200.05. Piper's new PT sits below the mean but above the stock. Recent analyst activity shows a string of upgrades, including Needham, UBS, and Wells Fargo, with only one downgrade in the past 30 days. EPS revisions are mixed: near-term estimates have been cut (9 down in 30 days for the current quarter), while next year's estimates have been raised (8 up). No insider or congressional trades were recorded. Institutional activity is divergent — FMR added 35.9% while Renaissance and Point72 trimmed heavily. Short interest is elevated at a 66.8% ratio. The double upgrade from a top-tier firm adds bullish momentum, but high short interest and institutional selling create a contrarian tension ahead of the July 29 earnings report.
Impact Score
Consensus & Targets
Of 44 analysts covering BIIB, 27 rate it Buy (61.4%), 16 Hold (36.4%), and 1 Sell (2.3%). The consensus is clearly bullish, and Piper's upgrade aligns with the majority view.
The mean price target is $220.63, median $217.5, high $300, and low $150. At $200.05, the stock has 10.3% upside to the mean. Piper's $214 target is below the mean and median but above the current price and its prior $177 target.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-06-08 | Needham | upgrade | Buy | $255.00 |
| 2026-05-27 | RBC Capital | maintain | Outperform | $227.00 |
| 2026-05-15 | Piper Sandler | reiterate | Overweight | $225.00 |
| 2026-05-01 | Citigroup | maintain | Neutral | $200.00 |
| 2026-04-30 | Morgan Stanley | maintain | Equal-Weight | $206.00 |
| 2026-04-30 | RBC Capital | maintain | Outperform | $222.00 |
| 2026-04-30 | Guggenheim | maintain | Buy | $260.00 |
| 2026-04-30 | Wedbush | maintain | Neutral | $196.00 |
| 2026-04-22 | UBS | upgrade | Buy | $225.00 |
| 2026-04-20 | Wells Fargo | upgrade | Overweight | $250.00 |
In the last 30 days, there has been 1 upgrade (this one) and 0 downgrades. EPS revisions are mixed: current-quarter estimates saw 9 downward revisions in 30 days, while next-year estimates saw 8 upward revisions. Near-term headwinds are offset by longer-term optimism.
Firm Track Record — Piper Sandler
Piper Sandler accuracy: 54% on 3763 calls | avg return: 3.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 2/2 | 13% | top tier |
| Morgan Stanley | 83% | 5/6 | 5.5% | top tier |
| Piper Sandler | 71% | 5/7 | 1.6% | top tier |
| Wedbush | 67% | 4/6 | 2.1% | top tier |
| JP Morgan | 67% | 2/3 | 2.5% | top tier |
| HC Wainwright & Co. | 57% | 4/7 | 1.4% | above average |
| UBS | 50% | 1/2 | 0.6% | below average |
| Barclays | 50% | 2/4 | -2.8% | below average |
| Canaccord Genuity | 50% | 1/2 | -2.1% | below average |
| Goldman Sachs | 50% | 1/2 | -0.1% | below average |
Piper Sandler has a 71% accuracy rate on BIIB (5 of 7 calls) with an average return of 1.6%, ranking as a top-tier firm. The best-performing firm on BIIB is Jefferies (100% on 2 calls, avg return 13%), while the worst is Mizuho (33% on 3 calls, avg return -5%).
Earnings Estimates
Next earnings: Jul 29, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $1.94 | $-21.10 — $4.26 | $2.4B | ↑1 ↓0 |
| +1q | $3.94 | $3.20 — $4.66 | $2.6B | ↑0 ↓0 |
| +1y | $16.65 | $14.25 — $19.35 | $10.4B | ↑2 ↓0 |
| 0y | $13.34 | $-10.65 — $15.90 | $10.0B | ↑0 ↓0 |
Cross-Platform Signals
No insider trades or congressional activity were reported. Institutional moves are mixed: FMR LLC added 35.9% ($2.35B), but Renaissance Technologies trimmed 49% and Point72 trimmed 71.2%. Short interest is high at a 66.8% ratio, indicating significant bearish positioning. The analyst upgrade diverges from institutional trimming and elevated short interest.
Actionable Insight
Piper's double upgrade adds to a growing bullish consensus, but the high short interest and institutional selling suggest a tug-of-war. Traders should watch the July 29 earnings report as a potential catalyst to resolve the divergence.
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 13, 2026
1d ago
|
ANALYST-UPGRADE
| $176.40 awaiting T+1 | awaiting T+1 | — | $200.05 (+13.41%) |
|
Jun 8, 2026
6d ago
|
ANALYST-UPGRADE
| $194.60 awaiting T+1 | awaiting T+1 | — | $200.05 (+2.80%) |
|
Jun 4, 2026
11d ago
|
Press Release
| $195.82 $195.30 | ▼ −0.27% | ▲ +2.33% | $200.05 (+2.16%) |
|
Jun 1, 2026
14d ago
|
Press Release
| $192.22 $188.66 | ▼ −1.85% | ▼ −2.00% | $200.05 (+4.08%) |
|
May 31, 2026
14d ago
|
ANALYST-UPGRADE
| $156.63 $154.99 | ▼ −1.05% | ▼ −1.18% | $200.05 (+27.72%) |
|
May 22, 2026
23d ago
|
ANALYST-UPGRADE
| $190.12 $187.84 | ▼ −1.20% | ▼ −0.81% | $200.05 (+5.22%) |
|
May 21, 2026
24d ago
|
Press Release
| $193.85 $193.07 | ▲ +0.40% | ▲ +0.99% | $200.05 (−3.20%) |
|
May 20, 2026
25d ago
|
ANALYST-UPGRADE
| $183.33 $185.18 | ▲ +1.01% | ▲ +1.66% | $200.05 (+9.12%) |
|
May 14, 2026
4w ago
|
ANALYST-UPGRADE
| $178.76 $180.47 | ▲ +0.96% | ▲ +0.18% | $200.05 (+11.91%) |
|
May 14, 2026
4w ago
|
Press Release
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $200.05 (+4.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access